INTI
Price
$0.05
Change
-$0.01 (-16.67%)
Updated
Oct 9 closing price
Capitalization
8.26M
Intraday Buy/Sell Signals
ISCO
Price
$0.15
Change
-$0.00 (-0.00%)
Updated
Oct 14 closing price
Capitalization
1.2M
Intraday Buy/Sell Signals
Interact to see
Advertisement

INTI vs ISCO

Header iconINTI vs ISCO Comparison
Open Charts INTI vs ISCOBanner chart's image
Inhibitor Therapeutics
Price$0.05
Change-$0.01 (-16.67%)
Volume$500
Capitalization8.26M
International Stem Cell
Price$0.15
Change-$0.00 (-0.00%)
Volume$3.09K
Capitalization1.2M
INTI vs ISCO Comparison Chart in %
INTI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ISCO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
INTI vs. ISCO commentary
Oct 17, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INTI is a Hold and ISCO is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 17, 2025
Stock price -- (INTI: $0.05 vs. ISCO: $0.15)
Brand notoriety: INTI and ISCO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INTI: 3% vs. ISCO: 62%
Market capitalization -- INTI: $8.26M vs. ISCO: $1.2M
INTI [@Biotechnology] is valued at $8.26M. ISCO’s [@Biotechnology] market capitalization is $1.2M. The market cap for tickers in the [@Biotechnology] industry ranges from $105.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.02B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INTI’s FA Score shows that 0 FA rating(s) are green whileISCO’s FA Score has 1 green FA rating(s).

  • INTI’s FA Score: 0 green, 5 red.
  • ISCO’s FA Score: 1 green, 4 red.
According to our system of comparison, ISCO is a better buy in the long-term than INTI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INTI’s TA Score shows that 2 TA indicator(s) are bullish while ISCO’s TA Score has 4 bullish TA indicator(s).

  • INTI’s TA Score: 2 bullish, 5 bearish.
  • ISCO’s TA Score: 4 bullish, 2 bearish.
According to our system of comparison, ISCO is a better buy in the short-term than INTI.

Price Growth

INTI (@Biotechnology) experienced а -20.00% price change this week, while ISCO (@Biotechnology) price change was +4.17% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.44%. For the same industry, the average monthly price growth was +17.42%, and the average quarterly price growth was +81.94%.

Industries' Descriptions

@Biotechnology (+0.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
INTI($8.26M) has a higher market cap than ISCO($1.2M). ISCO YTD gains are higher at: 84.502 vs. INTI (-20.399). ISCO has higher annual earnings (EBITDA): 128K vs. INTI (-3.67M). INTI has more cash in the bank: 3.74M vs. ISCO (920K). INTI has less debt than ISCO: INTI (78.1K) vs ISCO (3.85M). ISCO has higher revenues than INTI: ISCO (9.2M) vs INTI (0).
INTIISCOINTI / ISCO
Capitalization8.26M1.2M687%
EBITDA-3.67M128K-2,865%
Gain YTD-20.39984.502-24%
P/E RatioN/AN/A-
Revenue09.2M-
Total Cash3.74M920K406%
Total Debt78.1K3.85M2%
FUNDAMENTALS RATINGS
INTI vs ISCO: Fundamental Ratings
INTI
ISCO
OUTLOOK RATING
1..100
9235
VALUATION
overvalued / fair valued / undervalued
1..100
55
Fair valued
7
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
5941
P/E GROWTH RATING
1..100
8787
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ISCO's Valuation (7) in the null industry is somewhat better than the same rating for INTI (55). This means that ISCO’s stock grew somewhat faster than INTI’s over the last 12 months.

ISCO's Profit vs Risk Rating (100) in the null industry is in the same range as INTI (100). This means that ISCO’s stock grew similarly to INTI’s over the last 12 months.

INTI's SMR Rating (99) in the null industry is in the same range as ISCO (100). This means that INTI’s stock grew similarly to ISCO’s over the last 12 months.

ISCO's Price Growth Rating (41) in the null industry is in the same range as INTI (59). This means that ISCO’s stock grew similarly to INTI’s over the last 12 months.

ISCO's P/E Growth Rating (87) in the null industry is in the same range as INTI (87). This means that ISCO’s stock grew similarly to INTI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INTIISCO
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
87%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
82%
MACD
ODDS (%)
Bearish Trend 3 days ago
88%
Bullish Trend 3 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
75%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
68%
Bullish Trend 3 days ago
76%
Advances
ODDS (%)
N/A
Bullish Trend 3 days ago
66%
Declines
ODDS (%)
Bearish Trend 8 days ago
88%
N/A
BollingerBands
ODDS (%)
N/A
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bullish Trend 3 days ago
79%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
INTI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ISCO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
FSBC33.051.36
+4.29%
Five Star Bancorp
UNF163.214.69
+2.96%
Unifirst Corp
RCEL5.250.02
+0.38%
Avita Medical
RCI36.77N/A
N/A
Rogers Communications
NCPL2.30-0.06
-2.42%
NETCAPITAL INC.

INTI and

Correlation & Price change

A.I.dvisor tells us that INTI and QRON have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that INTI and QRON's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INTI
1D Price
Change %
INTI100%
N/A
QRON - INTI
24%
Poorly correlated
N/A
DWTX - INTI
23%
Poorly correlated
+0.16%
IVEVF - INTI
17%
Poorly correlated
N/A
IVBXF - INTI
11%
Poorly correlated
-4.17%
ISCO - INTI
7%
Poorly correlated
+1.35%
More

ISCO and

Correlation & Price change

A.I.dvisor tells us that ISCO and HNSBF have been poorly correlated (+22% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ISCO and HNSBF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ISCO
1D Price
Change %
ISCO100%
+1.35%
HNSBF - ISCO
22%
Poorly correlated
N/A
CRDF - ISCO
20%
Poorly correlated
+0.44%
LIXT - ISCO
7%
Poorly correlated
+2.53%
INTI - ISCO
7%
Poorly correlated
N/A
INRLF - ISCO
5%
Poorly correlated
N/A
More